サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1262040

前立腺肥大症治療市場- 世界の産業規模、シェア、動向、競合、機会、予測、2018-2028薬物治療別、外科的治療別、エンドユーザー別、地域別分析

Benign Prostate Hyperplasia Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Drug Treatment, By Surgical Treatment, By End User, By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 113 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

前立腺肥大症治療市場- 世界の産業規模、シェア、動向、競合、機会、予測、2018-2028薬物治療別、外科的治療別、エンドユーザー別、地域別分析
出版日: 2023年04月01日
発行: TechSci Research
ページ情報: 英文 113 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の前立腺肥大症（BPH）治療市場は、男性老年人口の増加、前立腺肥大症に関連する泌尿器疾患の増加により、予測期間2024-2028年に著しい成長を遂げると予測されています。

Global Cancer Observatoryによると、2020年には世界中で約19,292,789件の新規がん患者が報告され、その中でも前立腺がんが最も多く、14,14,259件のがん患者が報告されました。また、前立腺の早期診断・発見に対する国民の認識不足が、前立腺肥大症治療市場の成長をさらに促進すると予想されます。

製品の発売が市場を押し上げる

手術は薬で治療するよりも優れた選択肢ですが、手術で切った傷や火傷が術後に体に与える害のため、患者さんは薬を選択する傾向があります。しかし、低侵襲手術の開発により、患者の意識は変化し、手術機器メーカーは競合優位に立っています。例えば、テレフレックス社は2020年8月にBPHを治療するための改良型組織制御システム「ウロリフト」を発売しました。尿道を開くために、前立腺小葉を後退した姿勢に保つ小さなインプラントをシステムに入れるかもしれないです。大きな側葉や閉塞性正中葉など、前立腺の解剖学的構造が困難な患者が、この装置のターゲット集団となります。これらの製品の発売は、市場の成長を促進すると予想されます。

研究開発の成長

前立腺がんのような生命を脅かすさまざまな疾患の治療のために、新しい薬剤や手術を開発する必要性が高まっているため、研究開発の手法や活動が急速に進歩し、市場の成長を後押ししています。Clinicaltrials.govによると、前立腺肥大症（BPH）治療に関して、世界中で17の臨床試験が異なる開発段階にあることが示されています。これは、良性前立腺肥大症（BPH）治療薬の開発のために、世界中で多くの研究開発が行われていることを明確に示しており、それによって市場の成長を支えています。しかし、2017年2月、がんにおける共同研究活動を意図して、All India Institute of Ayurveda（AIIA）とNational Institute of Cancer Prevention and Research（NICPR-ICMR）の共同事業として、The Centre for Integrative Oncology（CIO）が設立されました。

ヘルスケアへの投資の高まり

高度な外科療法は非常に高価であるため、がん治療には政府による財政支援が行われています。アユシュマン社の設立

Bharat Health and Wellness Centers（AB-HWC）は、2018年2月にインド政府によって、3つの一般的ながん、すなわち口腔がん、乳がん、子宮頸がんの診断とスクリーニングのために発表されました。2018年に開始された別のイニシアチブ、すなわちPradhan Mantri Jan Arogya Yojanaは、その規範に従って一定の支出まで、がんの治療施設を急増させました。化学療法と放射線療法のパッケージは、外科的腫瘍学とともに、この制度の下でインパネリングされた病院でがん治療の一部としてカバーされ、合計435の処置ががん治療のために定義されています。

利用可能なカスタマイズ

与えられた市場データをもとに、TechSci Researchは企業の特定のニーズに応じてカスタマイズを提供します。本レポートでは、以下のカスタマイズが可能です：

会社情報

  • 追加市場プレイヤー（最大5社）の詳細分析およびプロファイリング

目次

第1章 概要

  • 市場の定義
  • 市場の範囲
    • 対象市場
    • 研究対象年
    • 主な市場セグメンテーション

第2章 調査手法

  • 調査目的
  • ベースライン調査手法
  • 主要産業パートナー
  • 主な協会と二次情報
  • 調査手法
  • データの三角測量と検証
  • 前提条件と限界

第3章 エグゼクティブサマリー

  • 市場概要
  • 主要市場セグメンテーションの概要
  • 主要市場プレイヤーの概要
  • 主要地域/国の概要
  • 市場促進要因・課題・動向

第4章 VOC (顧客の声)

第5章 BPHデバイスの世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬物治療別（α遮断薬、5-α還元酵素阻害薬、ホスホジエステラーゼ-5阻害薬）
    • 手術療法別（経尿道的前立腺切除術（TURP）、前立腺尿道リフト（PUL）、前立腺切除術、レーザー手術、経尿道的マイクロ波法（TUMT）、経尿道的前立腺針切除術（TUNA）、その他（Rezum療法、Urolift療法、その他）
    • エンドユーザー別（病院・診療所、外来手術センター、その他）
    • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
    • 企業別（2022年）
  • マーケットマップ
    • 薬物治療別
    • 外科的治療別もの
    • エンドユーザー別
    • 地域別

第6章 北米のBPHデバイス市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬物治療別
    • 外科的治療別もの
    • エンドユーザー別
    • 国別
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州BPH治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬物治療別
    • 外科的治療別もの
    • エンドユーザー別
    • 国別
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の前立腺肥大症治療薬の市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬物治療別
    • 外科的治療別もの
    • エンドユーザー別
    • 国別
  • アジア太平洋：国別分析
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア

第9章 南米BPH治療市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬物治療別
    • 外科的治療別もの
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのBPH治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • 薬物治療別
    • 外科的治療別もの
    • エンドユーザー別
    • 国別
  • MEA：国別分析
    • UAE BPH治療
    • サウジアラビアのBPH治療
    • 南アフリカBPH治療
    • トルコBPH治療
    • エジプトBPH治療

第11章 市場力学

  • 促進要因
    • 前立腺肥大症の有病率の増加
    • 老年人口の増加
    • 技術の進歩
  • 課題すること
    • 高額な手続き費用
    • 技術に伴う副作用
    • 侵襲的な手術を行うためのスキルドプロフェッショナルの不足

第12章 市場動向と開拓

  • 新薬の開発
  • 新サージェリーの開発

第13章 臨床試験分析

  • 進行中の臨床試験
  • 終了した臨床試験
  • 終了した臨床試験
  • パイプラインの内訳（開発段階別
  • パイプラインの内訳（ステータス別
  • パイプラインの内訳（研究タイプ別
  • パイプラインの地域別内訳
  • クリニカル・トライアル・ヒートマップ

第14章 競合情勢について

  • 事業概要
  • 提供製品
  • 最近の開発状況
  • 財務状況（上場企業の場合）
  • 主要な人員
    • Boston Scientific Corporation
    • Coloplast Corporation
    • Teleflex Incorporated
    • Olympus Corporation
    • Glaxo Smith Kline PLC
    • Eli Lily
    • Abott Laboratories
    • Medifocus Inc.
    • Urologix, LLC
    • Pfizer Inc

第15章 戦略的な提言

第16章 調査会社について・免責事項

目次
Product Code: 14694

Global Benign Prostate Hyperplasia (BPH) Treatment Market is anticipated to observe impressive growth during the forecast period, 2024-2028, owing prevalence of benign prostatic hyperplasia rising global male geriatric population, rise in urological disorders associated with BPH. According to Global Cancer Observatory, in 2020, around 19,292,789 new cancer cases were reported worldwide, among which Prostate Cancer was the most prevalent type of cancer, accounting for 14,14,259 cases 2020. Additionally, the lack of awareness among the public for early prostate diagnosis and detection is further expected to drive the growth of the Benign Prostate Hyperplasia (BPH) Treatment Market.

The growing prevalence of fatal diseases has significantly increased the demand for different types of drugs and surgeries. Additionally, expansion in research & development activities being initiated by various governments, ambulatory surgical centers, and pharmaceutical companies across the globe is further expected to create opportunities for the growth of the Benign Prostate Hyperplasia (BPH) Treatment market in the coming years. According to Statista Research Department, as of now, the United States will be the leading country worldwide in terms of spending on research and development, with expenditure exceeding around USD679.4 billion.

According to the Cancer fact sheet, the cancer rates are highest in Australia/New Zealand and North America. Prostate cancer is the fourth most common cancer overall and the second most common cancer in men.

Product Launches Boost Market

Surgery is a superior alternative to treating BPH with medicine; however, due to the post-operative harm that surgical cuts and burns do to the body, patients tend to choose medication. Patients' perceptions have changed as a result of the development of minimally invasive techniques and surgical equipment makers now have a competitive advantage. For instance, Teleflex Inc. launched the UroLift improved tissue control system in August 2020 to treat BPH. To open the urethra, small implants that keep the prostate lobes in their retracted posture might be placed into the system. Patients with challenging prostatic anatomy, such as those who have large lateral lobes or an obstructive median lobe, are the target population for the device. These product launches are anticipated to boost the growth of the market.

Growth in Research & Development

Rapid advancements in research and development (R&D) practices and activities are propelling the growth of the market on account of the growing need for developing novel drug/surgery for the treatment of different life-threatening diseases like prostate cancer. According to Clinicaltrials.gov, 17 clinical trials are in different phases of development across the globe for Benign Prostate Hyperplasia (BPH) Treatment. This clearly indicates that a lot of R&D is being done across the globe for developing Benign Prostate Hyperplasia (BPH) Treatment., thereby supporting the growth of the market. However, in February 2017, The Centre for Integrative Oncology (CIO) was established as a joint venture of the All India Institute of Ayurveda (AIIA) and the National Institute of Cancer Prevention and Research (NICPR-ICMR) with the intention of collaborative research activities in cancer.

Rising Investment in Healthcare

Advanced surgical therapies are very expensive; therefore, financial assistance is provided by the government for cancer treatment. An establishment of Ayushman

Bharat Health and Wellness Centers (AB-HWCs) were announced by the Government of India in February 2018 for the diagnosis and screening of three common cancers, i.e., oral, breast, and cervical. Another initiative launched in 2018, namely Pradhan Mantri Jan Arogya Yojana, surged treatment facilities for cancer up to a certain expenditure as per their norms. The chemotherapy and radiotherapy packages, along with surgical oncology, are covered as part of cancer treatment in the impaneled hospitals under the scheme, and a total of 435 procedures have been defined for the treatment of cancer.

Market Segmentation

The Global Benign Prostate Hyperplasia (BPH) Treatment Market can be segmented based on drug treatment, surgical treatment, end user, region, and competitional landscape. Based on drug treatment, the market can be categorized into alpha-blockers, 5-alpha reductase inhibitors, and Phosphodiesterase-5 Inhibitors. Based on surgical treatment, the market can be fragmented into transurethral resection of the prostate (TURP), prostatic urethral lift (PUL), Prostatectomy, laser surgery, transurethral microwave Technique (TUMT), transurethral needle ablation of the prostate (TUNA), and others. Based on end users, the market can be grouped into hospitals and clinics, ambulatory surgical centers, and others.

Company Profiles

Boston Scientific Corporation, Coloplast Corporation, Teleflex Incorporated, Olympus Corporation, Glaxo Smith Kline PLC, Eli Lily, Abbott Laboratories, Medifocus Inc., Urologix, LLC, and Pfizer Inc. are some of the key players operating in the Global Benign Prostate Hyperplasia (BPH) Treatment market.

Report Scope

In this report, Global Benign Prostate Hyperplasia (BPH) Treatment Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Benign Prostate Hyperplasia (BPH) Treatment Market, By Drug Treatment:

  • Alpha Blockers
  • 5-Alpha Reductase Inhibitors
  • Phosphodiesterase-5 inhibitors

Benign Prostate Hyperplasia (BPH) Treatment Market, By Surgical Treatment:

  • Transurethral resection of the prostate (TURP)
  • Prostatic Urethral Lift (PUL)
  • Prostatectomy
  • Laser surgery
  • Transurethral microwave Technique (TUMT)
  • Transurethral needle ablation of the prostate (TUNA)
  • Others

Benign Prostate Hyperplasia (BPH) Treatment Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Benign Prostate Hyperplasia (BPH) Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Benign Prostate Hyperplasia (BPH) Treatment market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global BPH Devices Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Treatment (Alpha Blockers, 5-Alpha Reductase Inhibitors, and Phosphodiesterase-5 Inhibitors)
    • 5.2.2. By Surgical Treatment (Transurethral resection of the prostate (TURP), Prostatic Urethral Lift (PUL), Prostatectomy, laser surgery, Transurethral microwave Technique (TUMT), Transurethral needle ablation of the prostate (TUNA), and others (Rezum therapy, Urolift therapy, etc)
    • 5.2.3. By End User (hospitals and clinics, ambulatory surgical centres, and Others)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Drug Treatment
    • 5.3.2. By Surgical Treatment
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America BPH Devices Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Treatment
    • 6.2.2. By Surgical Treatment
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States BPH Devices Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Treatment
        • 6.3.1.2.2. By Surgical Treatment
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada BPH Devices Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Treatment
        • 6.3.2.2.2. By Surgical Treatment
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico BPH Devices Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Treatment
        • 6.3.3.2.2. By Surgical Treatment
        • 6.3.3.2.3. By End User

7. Europe BPH Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Treatment
    • 7.2.2. By Surgical Treatment
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France BPH Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Treatment
        • 7.3.1.2.2. By Surgical Treatment
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany BPH Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Treatment
        • 7.3.2.2.2. By Surgical Treatment
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom BPH Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Treatment
        • 7.3.3.2.2. By Surgical Treatment
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy BPH Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Treatment
        • 7.3.4.2.2. By Surgical Treatment
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain BPH Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Treatment
        • 7.3.5.2.2. By Surgical Treatment
        • 7.3.5.2.3. By End User

8. Asia-Pacific BPH Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Treatment
    • 8.2.2. By Surgical Treatment
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China BPH Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Treatment
        • 8.3.1.2.2. By Surgical Treatment
        • 8.3.1.2.3. By End User
    • 8.3.2. Japan BPH Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Treatment
        • 8.3.2.2.2. By Surgical Treatment
        • 8.3.2.2.3. By End User
    • 8.3.3. India BPH Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Treatment
        • 8.3.3.2.2. By Surgical Treatment
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea BPH Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Treatment
        • 8.3.4.2.2. By Surgical Treatment
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia BPH Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Treatment
        • 8.3.5.2.2. By Surgical Treatment
        • 8.3.5.2.3. By End User

9. South America BPH Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Treatment
    • 9.2.2. By Surgical Treatment
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil BPH Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Treatment
        • 9.3.1.2.2. By Surgical Treatment
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina BPH Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Treatment
        • 9.3.2.2.2. By Surgical Treatment
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia BPH Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Treatment
        • 9.3.3.2.2. By Surgical Treatment
        • 9.3.3.2.3. By End User

10. Middle East and Africa BPH Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Treatment
    • 10.2.2. By Surgical Treatment
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE BPH Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Treatment
        • 10.3.1.2.2. By Surgical Treatment
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia BPH Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Treatment
        • 10.3.2.2.2. By Surgical Treatment
        • 10.3.2.2.3. By End User
    • 10.3.3. South Africa BPH Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Treatment
        • 10.3.3.2.2. By Surgical Treatment
        • 10.3.3.2.3. By End User
    • 10.3.4. Turkey BPH Treatment Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Drug Treatment
        • 10.3.4.2.2. By Surgical Treatment
        • 10.3.4.2.3. By End User
    • 10.3.5. Egypt BPH Treatment Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Drug Treatment
        • 10.3.5.2.2. By Surgical Treatment
        • 10.3.5.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Increasing prevalence of Benign Prostate Hyperplasia
    • 11.1.2. Growing geriatric population
    • 11.1.3. Technological Advancement
  • 11.2. Challenges
    • 11.2.1. High Cost of Procedure
    • 11.2.2. Side effects associated with the technique
    • 11.2.3. Lack of Skilled Professionals to conduct invasive surgeries

12. Market Trends & Developments

  • 12.1. Development of new drugs
  • 12.2. Development of new surgeries

13. Clinical Trial Analysis

  • 13.1. Ongoing Clinical Trials
  • 13.2. Completed Clinical Trials
  • 13.3. Terminated Clinical Trials
  • 13.4. Breakdown of Pipeline, By Development Phase
  • 13.5. Breakdown of Pipeline, By Status
  • 13.6. Breakdown of Pipeline, By Study Type
  • 13.7. Breakdown of Pipeline, By Region
  • 13.8. Clinical Trials Heat Map

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (In Case of Listed Companies)
  • 14.5. Key Personnel
    • 14.5.1. Boston Scientific Corporation
    • 14.5.2. Coloplast Corporation
    • 14.5.3. Teleflex Incorporated
    • 14.5.4. Olympus Corporation
    • 14.5.5. Glaxo Smith Kline PLC
    • 14.5.6. Eli Lily
    • 14.5.7. Abott Laboratories
    • 14.5.8. Medifocus Inc.
    • 14.5.9. Urologix, LLC
    • 14.5.10. Pfizer Inc

15. Strategic Recommendations

16. About Us and Disclaimer